Biotech

Career and Jobs

Biotech Career and Jobs Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 25.11.2022.

#lifesciences
#biotech
#biopharma
#news
#BioSpace

@Biotechnology shared
On Nov 22, 2022
Gratitude and Optimism: This Thanksgiving, BioSpace Celebrates Biopharma Wins https://t.co/us6csayx5L https://t.co/ynXXAxFLY2
Open
Gratitude and Optimism: This Thanksgiving, BioSpace Celebrates Biopharma Wins

Gratitude and Optimism: This Thanksgiving, BioSpace Celebrates Biopharma Wins

In a volatile year, marked with challenges, BioSpace is taking a pause to reflect on the many “wins” in biopharma. 

@SynBioBeta shared
On Nov 21, 2022
The U.S. and its partners must step up with strategies for advancing #biotech that reinforce the aspirations of democratic societies, write @CSETGeorgetown's @AnnaPuglisi838 + @Andrew_Imbrie, @StanfordCISAC's @meganjpalmer & @Carnegie_Europe's @danbbaer https://t.co/KMzcQWWpMu .
Open
Democracies Must Empower a Biotech Future for All

Democracies Must Empower a Biotech Future for All

New innovations in biotechnology are driving rapid changes that will have far-reaching consequences. The United States and its partners need to be at the forefront of these advances.

@Labiotech_eu shared
On Nov 23, 2022
An impressive crowd gathered at Chiesi Pharmaceutical Group to mark the much-anticipated start of work of its Biotech Center of Excellence. 👇🏻 #biotech #lifesciences #news https://t.co/qGVeyg1BGw
Open
Chiesi marks start of Biotech Center of Excellence for the future of medicine in Parma

Chiesi marks start of Biotech Center of Excellence for the future of medicine in Parma

An impressive crowd gathered at Chiesi Pharmaceutical Group to mark the much-anticipated start of work of its Biotech Center of Excellence.

@Labiotech_eu shared
On Nov 25, 2022
This week, we have four guests, Carl Borrebaeck, and representatives from the companies Eversana, Concarlo Therapeutics, SOTIO Biotech. 👇🏻 #biotech #lifesciences #news https://t.co/C860sl79B3
Open
Beyond Biotech podcast 24: Concarlo Therapeutics, Eversana, Carl Borrebaeck, SOTIO Biotech

Beyond Biotech podcast 24: Concarlo Therapeutics, Eversana, Carl Borrebaeck, SOTIO Biotech

This week, we have four guests, Carl Borrebaeck, and representatives from the companies Eversana, Concarlo Therapeutics, SOTIO Biotech.

@MassBio shared
On Nov 21, 2022
The certificate programs are being designed to provide entry into #lifesciences careers such as technicians and lab assistants for individuals with a high school degree or its equivalent. https://t.co/74S7bEMCRc
Open
MassBio and Beacon Capital Partners are launching a life sciences workforce training center to meet growing demand

MassBio and Beacon Capital Partners are launching a life sciences workforce training center to meet growing demand

DORCHESTER, MA—November 21, 2022—Today, the Massachusetts Biotechnology Council (MassBio®) and Beacon Capital Partners announced a partnership to launch a nearly 4,000 square foot workforce ...

@SynBioBeta shared
On Nov 23, 2022
👉 TIME Magazine names MyBacon a Best Invention of 2022. 📣 Are you looking to domesticate wild organisms? Meet MicroByre. Read more: https://t.co/8jjG5rD5t8 Sign up for our newsletter at https://t.co/cwcwEWlpDK https://t.co/Bp1w8ypdIt
Open
@GENbio shared
On Nov 24, 2022
Researchers from the U.K. are working to boost protein secretion in a common biomanufacturing cell type by changing how the proteins are regulated. Read more: https://t.co/QWc1YazL9S https://t.co/DCINnf6YHZ
Open
Researchers Work to Boost Cell-Line Production with Synthetic Biology

Researchers Work to Boost Cell-Line Production with Synthetic Biology

Synthetic biology can be used to create a new expression system.

@JohnCendpts shared
On Nov 22, 2022
https://t.co/1xU3DIbTGx
Open
Days after reporting PhIII failure, GSK pulls BCMA drug from US market — but it's not giving up entirely yet

Days after reporting PhIII failure, GSK pulls BCMA drug from US market — but it's not giving up entirely yet

GSK is pulling its BCMA-targeting drug from the US market, ending a short, two-year run for a high-profile product that, among other things, was hailed for marking the pharma giant’s return ...